Tarsus Pharmaceuticals, Inc. TARS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s cash & equivalents?
- Tarsus Pharmaceuticals, Inc. (TARS) reported cash & equivalents of $104.19M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s cash & equivalents decreased by 41.6% year-over-year, from $178.35M to $104.19M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s cash & equivalents has grown at a 2.1% compound annual growth rate (CAGR), from $168.15M to $186.2M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.